ProQR Therapeutics (PRQR) Enterprise Value (2012 - 2026)

ProQR Therapeutics (PRQR) has reported Enterprise Value for 15 consecutive years, with -$92.3 million the latest figure, recorded in Q1 2026.

• Quarterly Enterprise Value rose 38.75% year-over-year to -$92.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$92.3 million (up 38.75% YoY) and the FY2025 annual result came in at -$105.2 million, up 38.15% from the prior year.
• Enterprise Value rose to -$92.3 million in Q1 2026 per PRQR's latest filing, from -$105.2 million in the prior quarter.
• Over the last five years, Enterprise Value for PRQR reached as high as -$92.3 million in Q1 2026 and fell as low as -$191.4 million in Q1 2022.
• A 5-year average of -$133.8 million and a median of -$135.3 million in 2023 frame the typical range for Enterprise Value.
• The largest YoY upside for Enterprise Value was 49.42% in 2022 against a maximum downside of 147.83% in 2022.
• Year by year, Enterprise Value stood at -$108.3 million in 2022, then retreated by 24.98% to -$135.3 million in 2023, then fell by 25.63% to -$170.0 million in 2024, then jumped by 38.15% to -$105.2 million in 2025, then increased by 12.24% to -$92.3 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$92.3 million, -$105.2 million, and -$121.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.